Drugs / Human pancreatic islet cells
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07592000 | Apr 2027 → Jan 2030 expected | chronic kidney disease, type 1 diabetes mellitus | University of Chicago | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06305286 | Mar 2024 → Mar 2029 expected | type 1 diabetes mellitus | University of Chicago | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human pancreatic islet cells | “Human pancreatic islet cells is considered investigational because it is not approved for use in the United States by the Food and Drug Administration (FDA).” NCT07592000 ↗1“Human pancreatic islet cells are considered investigational because they are not currently approved for use in the United States.” NCT06305286 ↗ |
| Action | Restore | “The goal of this study is to see whether these transplanted islet cells can take over insulin production for the body.” NCT07592000 ↗ |
| Modality | Cell therapy | “islet cells will be collected from the pancreas of a deceased organ donor and transplanted into the body.” NCT06305286 ↗ |
| Route | Other | “into the portal vein of the liver where the islet cells are delivered.” NCT06305286 ↗ |